Howard G. Welgus sold $125k of ARQT
director at Arcutis Biotherapeutics, Inc.. 10,000 shares at an average of $12.51, traded Dec 2, 2024, filed Dec 3, 2024.
Score components
- +15RoleDirector
- +11Trade size$125k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-24-000167, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.51 | $125k | 161,944 | Dec 3, 2024 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 11Weak | Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $64k 3,671 shares | -0% | |
| 10Weak | Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $21k 1,200 shares | -0% | |
| 29Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $921k 61,403 shares | -37% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $43k 3,263 shares | -2% | |
| 21Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $130k 10,000 shares | -7% | |
| 25Weak | Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $327k 25,015 shares | -3% | |
| 17Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $49k 3,773 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.